Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 29.269
- Book/Share 23.2357
- PB 6.5109
- Debt/Equity 0.7224
- CurrentRatio 0.8812
- ROIC 0.1851
- MktCap 287550186953.0
- FreeCF/Share 8.8572
- PFCF 16.8562
- PE 20.0535
- Debt/Assets 0.2985
- DivYield 0.0219
- ROE 0.3412
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVS | Citigroup | -- | Buy | -- | -- | Jan. 27, 2026 |
| Upgrade | NVS | Barclays | Underweight | Equal Weight | -- | -- | Jan. 6, 2026 |
| Upgrade | NVS | JP Morgan | Neutral | Overweight | -- | -- | Dec. 8, 2025 |
| Upgrade | NVS | Morgan Stanley | Equal Weight | Overweight | -- | -- | Dec. 3, 2025 |
| Upgrade | NVS | BofA Securities | Neutral | Buy | -- | -- | Nov. 25, 2025 |
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
News
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Read More
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Novartis (NVS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Novartis CEO on impact of 'most favored nation' drug pricing
Published: January 22, 2026 by: CNBC Television
Sentiment: Neutral
Novartis CEO Vas Narasimham, speaking with CNBC about lowering drug prices, said the focus should be on reducing patient out-of-pocket drug costs, not list or net prices, though believes progress is moving in the right direction.
Read More
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.
Published: January 22, 2026 by: CNBC Television
Sentiment: Neutral
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
Read More
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.
Read More
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Read More
Novartis (NVS) is a Top-Ranked Value Stock: Should You Buy?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
Published: January 13, 2026 by: Business Wire
Sentiment: Neutral
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction.
Read More
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Novartis eyes more bolt-on acquisitions, CEO says
Published: January 12, 2026 by: Reuters
Sentiment: Positive
Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said at a major industry conference that kicked off on Monday in San Francisco.
Read More
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
East Hanover, N.J., January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, …
Read More
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, Florida, will …
Read More
Novartis and US government reach agreement on lowering drug prices in the US
Published: December 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing, and research and development.
Read More
Novartis, Roche near US drug price deal, Bloomberg News reports
Published: December 17, 2025 by: Reuters
Sentiment: Positive
The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday citing people familiar with the situation.
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Published: December 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Read More
Here's Why Novartis (NVS) is a Strong Momentum Stock
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
Read More
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Read More
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Published: November 20, 2025 by: Benzinga
Sentiment: Positive
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.
Read More
Novartis to build manufacturing hub in North Carolina, creating 700 jobs
Published: November 19, 2025 by: Reuters
Sentiment: Positive
Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U.S. infrastructure investment over the next five years, the Swiss pharmaceuticals company said on Wednesday.
Read More
Novartis announces plans to build flagship manufacturing hub in North Carolina
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale.
Read More
Novartis announces plans to build flagship manufacturing hub in North Carolina
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale. This announcement is part of Novartis' $23 billion investment in US-based infrastructure over the next five years, designed to increase manufacturing capacity and enable 100% of the company's key medicines to be produced end-to-end in the US. As …
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Read More
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Steve Scala - TD Cowen, Research Division Xue Chen - Barclays Bank PLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Read More
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Read More
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883